Plasmablastic lymphoma was initially described as a variant of diffuse large B-cell lymphoma (DLBCL) involving the oral cavity of HIV+ patients and characterized by immunoblastic morphology and a plasma cell phenotype. However, other lymphomas may exhibit similar morphologic and immunophenotypic features. To determine the significance of plasmablastic differentiation in DLBCL and examine the heterogeneity of lymphomas with these characteristics, we examined 50 DLBCLs with low/absent CD20/CD79a and an immunophenotype indicative of terminal B-cell differentiation (MUM1/CD38/CD138/EMA-positive). We were able to define several distinct subgroups. Twenty-three tumors were classified as plasmablastic lymphoma of the oral mucosa type and showed a monomorphic population of immunoblasts with no or minimal plasmacytic differentiation. Most patients were HIV+ and EBV was positive in 74%. Eleven (48%) cases presented in the oral mucosa, but the remaining presented in other extranodal (39%) or nodal (13%) sites. Sixteen cases were classified as plasmablastic lymphoma with plasmacytic differentiation. These were composed predominantly of immunoblasts and plasmablasts, but in addition exhibited more differentiation to mature plasma cells. Only 33% were HIV+, EBV was detected in 62%, and 44% had nodal presentation. Nine cases, morphologically indistinguishable from the previous group, were secondary extramedullary plasmablastic tumors occurring in patients with prior or synchronous plasma cell neoplasms, classified as multiple myeloma in 7 of the 9. Two additional neoplasms were an HHV-8+ extracavitary variant of primary effusion lymphoma and an ALK+ DLBCL. HHV-8 was examined in 39 additional cases, and was negative in all. In conclusion, DLBCLs with plasmablastic differentiation are a heterogeneous group of neoplasms with different clinicopathological characteristics that may correspond to different entities.
From the *Hematopathology Section, Laboratory of Pathology, and Department of Hematology, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain; †Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD; ‡Laboratory of Pathology, Hospital Galdakao, Vizcaya, Spain; and §Hospital Prínceps d’Espanya, L’Hospitalet de Llobregat, University of Barcelona, Barcelona, Spain.
Supported in part by Grant La MaratóTV3 2000 TV2610, SAF 02/ 3261 from the Spanish Commision Interministerial de Ciencia y Tecnología, and Redes Temáticas de Cáncer and Linfomas C03/10 and G03/179 from Instituto de Salud Carlos III.
Reprints: Elías Campo, MD, Laboratory of Pathology, Hospital Clínic, Villarroel 170, 08036-Barcelona, Spain (e-mail: ECAMPO@clinic.ub.es).